Literature DB >> 21715594

The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Brian C DeHaven1, Kushol Gupta2, Stuart N Isaacs3,1.   

Abstract

The vaccinia virus A56 protein was one of the earliest-described poxvirus proteins with an identifiable activity. While originally characterized as a haemagglutinin protein, A56 has other functions as well. The A56 protein is capable of binding two viral proteins, a serine protease inhibitor (K2) and the vaccinia virus complement control protein (VCP), and anchoring them to the surface of infected cells. This is important; while both proteins have biologically relevant functions at the cell surface, neither one can locate there on its own. The A56-K2 complex reduces the amount of virus superinfecting an infected cell and also prevents the formation of syncytia by infected cells; the A56-VCP complex can protect infected cells from complement attack. Deletion of the A56R gene results in varying effects on vaccinia virus virulence. In addition, since the gene encoding the A56 protein is non-essential, it can be used as an insertion point for foreign genes and has been deleted in some viruses that are in clinical development as oncolytic agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715594      PMCID: PMC3353385          DOI: 10.1099/vir.0.030460-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  83 in total

1.  The cowpox virus fusion regulator proteins SPI-3 and hemagglutinin interact in infected and uninfected cells.

Authors:  Peter C Turner; Richard W Moyer
Journal:  Virology       Date:  2005-12-27       Impact factor: 3.616

2.  Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.

Authors:  M C Galmiche; J Goenaga; R Wittek; L Rindisbacher
Journal:  Virology       Date:  1999-02-01       Impact factor: 3.616

3.  Cellular mechanisms in the superinfection exclusion of vesicular stomatitis virus.

Authors:  K O Simon; J J Cardamone; P A Whitaker-Dowling; J S Youngner; C C Widnell
Journal:  Virology       Date:  1990-07       Impact factor: 3.616

4.  Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.

Authors:  Elizabeth A Moulton; Paula Bertram; Nanhai Chen; R Mark L Buller; John P Atkinson
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

5.  Molecular attenuation of vaccinia virus: mutant generation and animal characterization.

Authors:  M S Lee; J M Roos; L C McGuigan; K A Smith; N Cormier; L K Cohen; B E Roberts; L G Payne
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  Comparative proteomics of human monkeypox and vaccinia intracellular mature and extracellular enveloped virions.

Authors:  Nathan P Manes; Ryan D Estep; Heather M Mottaz; Ronald J Moore; Therese R W Clauss; Matthew E Monroe; Xiuxia Du; Joshua N Adkins; Scott W Wong; Richard D Smith
Journal:  J Proteome Res       Date:  2008-01-19       Impact factor: 4.466

7.  Vaccinia virus A56/K2 fusion regulatory protein interacts with the A16 and G9 subunits of the entry fusion complex.

Authors:  Timothy R Wagenaar; Suany Ojeda; Bernard Moss
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

8.  Origin of the vaccinia virus hemagglutinin.

Authors:  K E Blackman; H C Bubel
Journal:  J Virol       Date:  1972-02       Impact factor: 5.103

9.  Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence.

Authors:  S N Isaacs; G J Kotwal; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

10.  Regulation of complement activity by vaccinia virus complement-control protein.

Authors:  R McKenzie; G J Kotwal; B Moss; C H Hammer; M M Frank
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

View more
  11 in total

1.  The Ectodomain of the Vaccinia Virus Glycoprotein A34 Is Required for Cell Binding by Extracellular Virions and Contains a Large Region Capable of Interaction with Glycoprotein B5.

Authors:  Stephanie R Monticelli; Amalia K Earley; Jessica Tate; Brian M Ward
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Identification of SNPs associated with variola virus virulence.

Authors:  Anne Gatewood Hoen; Shea N Gardner; Jason H Moore
Journal:  BioData Min       Date:  2013-02-14       Impact factor: 2.522

3.  Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.

Authors:  Motomu Nakatake; Nozomi Kuwano; Emi Kaitsurumaru; Hajime Kurosaki; Takafumi Nakamura
Journal:  Mol Ther       Date:  2020-12-19       Impact factor: 11.454

4.  The Molluscum Contagiosum Gene MC021L Partially Compensates for the Loss of Its Vaccinia Virus Homolog, F13L.

Authors:  Stephanie R Monticelli; Peter Bryk; Brian M Ward
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

5.  Proteomic assessment of humoral immune responses in smallpox vaccine recipients.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Diane E Grill; Gregory A Poland
Journal:  Vaccine       Date:  2021-12-21       Impact factor: 3.641

6.  Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of superinfecting virions.

Authors:  Virginie Doceul; Michael Hollinshead; Adrien Breiman; Kathlyn Laval; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2012-05-23       Impact factor: 3.891

7.  Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus.

Authors:  Euna Cho; Eun Jin Ryu; Fen Jiang; Ung Bae Jeon; Mong Cho; Cy Hyun Kim; Miyoung Kim; Nam Deuk Kim; Tae-Ho Hwang
Journal:  Drug Des Devel Ther       Date:  2018-08-08       Impact factor: 4.162

8.  An increase in glycoprotein concentration on extracellular virions dramatically alters vaccinia virus infectivity and pathogenesis without impacting immunogenicity.

Authors:  Stephanie R Monticelli; Peter Bryk; Matthew G Brewer; Hector C Aguilar; Christopher C Norbury; Brian M Ward
Journal:  PLoS Pathog       Date:  2021-12-28       Impact factor: 6.823

9.  Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.

Authors:  Stephen Boulton; Joanna Poutou; Nikolas T Martin; Taha Azad; Ragunath Singaravelu; Mathieu J F Crupi; Taylor Jamieson; Xiaohong He; Ricardo Marius; Julia Petryk; Christiano Tanese de Souza; Bradley Austin; Zaid Taha; Jack Whelan; Sarwat T Khan; Adrian Pelin; Reza Rezaei; Abera Surendran; Sarah Tucker; Emily E F Brown; Jaahnavi Dave; Jean-Simon Diallo; Rebecca Auer; Jonathan B Angel; D William Cameron; Jean-Francois Cailhier; Réjean Lapointe; Kyle Potts; Douglas J Mahoney; John C Bell; Carolina S Ilkow
Journal:  Mol Ther       Date:  2021-10-20       Impact factor: 12.910

10.  Transport and stability of the vaccinia virus A34 protein is affected by the A33 protein.

Authors:  Adrien Breiman; David C J Carpentier; Helen A Ewles; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2012-12-19       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.